136 related articles for article (PubMed ID: 15828305)
1. [Detection of minimal residual disease in children with neuroblastoma].
De Moerloose B; Swerts K
Verh K Acad Geneeskd Belg; 2005; 67(1):33-44. PubMed ID: 15828305
[TBL] [Abstract][Full Text] [Related]
2. Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry.
Swerts K; De Moerloose B; Dhooge C; Brichard B; Benoit Y; Laureys G; Philippé J
Cytometry B Clin Cytom; 2004 Sep; 61(1):9-19. PubMed ID: 15351977
[TBL] [Abstract][Full Text] [Related]
3. Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma.
Ifversen MR; Kågedal B; Christensen LD; Rechnitzer C; Petersen BL; Heilmann C
Int J Oncol; 2005 Jul; 27(1):121-9. PubMed ID: 15942651
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
Cheung IY; Cheung NK
Clin Cancer Res; 2001 Jun; 7(6):1698-705. PubMed ID: 11410509
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma.
Komada Y; Zhang XL; Zhou YW; Inaba H; Deguchi T; Azuma E; Sakurai M
Cancer; 1998 Feb; 82(3):591-9. PubMed ID: 9452279
[TBL] [Abstract][Full Text] [Related]
7. [The identification of minimal residual disease in the bone marrow and peripheral blood in neuroblastoma. The prognostic and therapeutic implications].
Faulkner LB; Tamburini A; Tintori V; Paoli A; Tondo A; Bernini G; Medicina D; Brisigotti M; Corrias MV; Scaruffi P; Rosanda C; Lo Piccolo MS; Viscardi E; Milanaccio C; Garaventa A; De Bernardi B
Pediatr Med Chir; 1998; 20(3):175-8. PubMed ID: 9744008
[TBL] [Abstract][Full Text] [Related]
8. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.
Lambooy LH; Gidding CE; van den Heuvel LP; Hulsbergen-van de Kaa CA; Ligtenberg M; Bökkerink JP; De Abreu RA
Clin Cancer Res; 2003 Feb; 9(2):812-9. PubMed ID: 12576454
[TBL] [Abstract][Full Text] [Related]
9. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma.
Parareda A; Gallego S; Roma J; Llort A; Sábado C; Gros L; De Toledo JS
Oncol Rep; 2005 Oct; 14(4):1021-7. PubMed ID: 16142367
[TBL] [Abstract][Full Text] [Related]
11. Detecting minimal residual disease in neuroblastoma patients-the present state of the art.
Beiske K; Ambros PF; Burchill SA; Cheung IY; Swerts K
Cancer Lett; 2005 Oct; 228(1-2):229-40. PubMed ID: 15951104
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
13. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual marrow disease: detection and significance of isolated tumour cells in bone marrow.
Iorgulescu DG; Kiroff GK
ANZ J Surg; 2001 Jun; 71(6):365-76. PubMed ID: 11409023
[TBL] [Abstract][Full Text] [Related]
15. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
[TBL] [Abstract][Full Text] [Related]
16. [The morphological assessment of bone marrow infiltration in neuroblastoma].
Brisigotti M; Medicina D; Bercich L; Bonetti MF; Fabbretti G; Gambini C; Lo Piccolo MS; Milanaccio C; Rosanda C; Garaventa A; De Bernardi B; Callea F
Pediatr Med Chir; 1998; 20(3):169-74. PubMed ID: 9744007
[TBL] [Abstract][Full Text] [Related]
17. Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry.
Bozzi F; Gambirasio F; Luksch R; Collini P; Brando B; Fossati-Bellani F
Anticancer Res; 2006; 26(5A):3281-7. PubMed ID: 17094441
[TBL] [Abstract][Full Text] [Related]
18. Detection and treatment of minimal residual disease in high-risk neuroblastoma.
Reynolds CP
Pediatr Transplant; 2004 Jun; 8 Suppl 5():56-66. PubMed ID: 15125707
[TBL] [Abstract][Full Text] [Related]
19. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.
Cheung IY; Lo Piccolo MS; Kushner BH; Cheung NK
J Clin Oncol; 2003 Oct; 21(20):3853-8. PubMed ID: 14551304
[TBL] [Abstract][Full Text] [Related]
20. [Significance of application of immunocytochemical detection of GD2 antigen in bone marrow in neuroblastoma patients].
Bolek-Marzec K; Balwierz W; Wieczorek A; Szewczyk K
Przegl Lek; 2010; 67(6):409-12. PubMed ID: 21344771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
